Naburel is a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. It helps reduce joint pain, swelling and stiffness.
Nabumetone (Naburel) is a prodrug that is converted into its active form after liver metabolism, offering reduced renal and gastrointestinal side effects compared to conventional NSAIDs. It acts by inhibiting cyclooxygenase (COX) enzymes and provides effective relief from pain and inflammation in patients with chronic arthritis.
Naburel 500 mg Tablet: Each film-coated tablet contains Nabumetone USP 500 mg.
Naburel 750 mg Tablet: Each film-coated tablet contains Nabumetone USP 750 mg.
Naburel is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Route of administration: Oral
Dosage: Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose is 1000 mg taken as a single dose with or without food, some patients may obtain more symptomatic relief from 1500 mg to 2000 mg per day. Naburel can be given in either a single or twice-daily dose. Dosages greater than 2000 mg per day have not been studied; the lowest effective dose should be used for chronic treatment.
• Hypersensitivity to Nabumetone or any of its components.
• NSAIDs induced asthma, urticaria, or allergic type reactions.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID results in a dose-dependent decrease in prostaglandin synthesis and, secondarily, in a reduction of renal blood flow, which may precipitate overt renal decompensation. NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at a greater risk. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Gastrointestinal: Diarrhea, dyspepsia, abdominal pain, constipation, flatulence, nausea, positive stool guaiac, dry mouth, gastritis, stomatitis, vomiting.
Central Nervous System: Dizziness, headache, fatigue, increased sweating, insomnia, nervousness, somnolence.
Dermatologic: Pruritus, rash.
Special Senses: Tinnitus.
Miscellaneous: Edema.
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
Use in pregnancy: Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. This drug should be used during pregnancy only if dearly needed. Use of Nabumetone during the third trimester of pregnancy is not recommended.
Use in renal impairment: Caution should be taken in prescribing Nabumetone to patients with moderate or severe renal insufficiency The maximum starting doses of Nabumetone in patients with moderate or severe renal insufficiency should not exceed 750 mg or 500 mg, respectively once daily. Following careful monitoring of renal function in patients with moderate or severe renal insufficiency, daily doses may be increased to a maximum of 1500 mg and 1000 mg, respectively.
Use in lactation: Nabumetone is not recommended for use in nursing mothers because of the possible adverse effects of prostaglandin-synthesis-inhibiting drugs on neonates.
Use in children & adolescents: Safety and effectiveness in pediatric patients have not been established.
Naburel 500 mg Tablet: Each box contains 30’s Tablets in blister pack.
Naburel 750 mg Tablet: Each box contains 20’s Tablets in blister pack.
FR
DE